Biomay and Synthego Partner on Integrated cGMP CRISPR Manufacturing
- Biomay will resell its mRNA, LNP formulation, aseptic fill-finish, plasmid DNA, recombinant proteins, and Cas9 production services to Synthego customers under a non-exclusive collaboration.
- Synthego customers gain access to Biomay's off-the-shelf and cGMP Cas9 products, plus integrated cGMP solutions combining mRNA manufacturing, LNP formulation, fill-finish, and Cas9 production with Synthego's sgRNA expertise.
- The partnership streamlines end-to-end manufacturing pathways for CRISPR-based therapies across North America, including custom cGMP mRNA and LNP formulation services for gene-editing programs.
Operational Impact
CDMO directors evaluating CRISPR manufacturing capacity should note that Biomay's existing cGMP mRNA, LNP, fill-finish, and Cas9 production capabilities are now marketed directly to Synthego's customer base, potentially reducing standalone vendor selection complexity for integrated gene-editing programs.
Source: Contract Pharma Breaking News RSS
Lonza and Asimov Partner on Scalable Lentiviral Vector Manufacturing for Gene Therapy
- Lonza and Asimov are collaborating to advance lentiviral vector manufacturing using Asimov's LV Edge stable producer cell lines combined with Lonza's process development, scale-up, and GMP capabilities.
- The partnership addresses manufacturability challenges in current multi-plasmid transient transfection methods by developing stable, program-specific production strategies to improve scalability and batch-to-batch consistency.
- The companies will establish a feasibility-first framework spanning transgene optimization, cell line development, process development, analytics, scale-up, GMP production, and CMC readiness for in vivo and ex vivo lentiviral programs.
Operational Impact
Lonza's integration of Asimov's LV Edge stable producer cell lines into its GMP manufacturing platform expands the CDMO's specialized modalities portfolio and positions it as a preferred partner for developers seeking earlier manufacturability input and faster paths to clinical and commercial lentiviral vector production.
Source: Contract Pharma Breaking News RSS